IMM2902, a HER2/SIRPα Bispecific MAb-Trap Antibody-receptor Fusion Protein, in Patients with HER2-expressing Advanced Solid Tumors

Clinical trial NCT05076591 · SUSPENDED

Trial details

NCT number: NCT05076591
Sponsor: ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
Status: SUSPENDED
Phase: Phase 1
Study type: INTERVENTIONAL

Advanced Solid Tumor Advanced Breast Cancer Advanced Gastric Cancer

Start date: 2022-06-20
Primary completion: 2024-12-01
Enrollment: 135

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.